ClinOne Releases Integrated Dynamic eLearning Into Its Core Technology
DENVER, March 20, 2018 /PRNewswire/ — ClinOne, a mobile clinical trial management solution, has announced the release of its eLearning module into its suite of technologies to deliver seamless, dynamic training to research sites during trial participation.
“We are pleased to provide sponsors and research institutions another value-added integrated technology into our suite of solutions. Patients, research institutions and sponsors continue to drive our product direction and we’re now able to include an electronic training module into our technology suite,” said Rob Bohacs, CEO of ClinOne.
Dynamic training is a unique technology currently not supported by other technologies across the eLearning environment, where certain events within a study or site level activity trigger additional training modules. Instead of requiring research institutions to complete training in a single instance, ClinOne’s technology assesses the types of patients on the study, which arm patients were randomized into, and provides individual site users with a learning path. This eliminates unnecessary training and saves valuable time and costs.
“Perhaps the more important element of the technology is that we a simple user interface and automated compliance reporting for institutions and study sponsors. There’s no longer a need to incorporate additional vendors,” Bohacs said. “Our primary objective is to simplify the process of institutional training, reduce time, cost, and provide simple reporting/documentation on completed training modules.”
The ClinOne solution and its suite of products were created to improve clinical trial enrollment, retention and research site compliance. The company’s sole mission is to allow important trial details to be at the fingertips of participating researchers and patients. Currently, more than 2,600 active clinical trials in 50 countries rely on ClinOne’s suite of technologies. Visit www.clinone.com for more information.
SOURCE ClinOne, Inc.